AAAAI 2021: PHA121 achieved positive results in the treatment of hereditary angioedema (HAE).

Hereditary angioedema (HAE) is a disease characterized by recurrent angioedema, which is not accompanied by urticaria or itching and most commonly affects mucous tissue in the skin or upper respiratory tract and gastrointestinal tract.
biopharmaceutical company Pharvaris recently announced that phAA121 (PHA-022121) for the treatment of hereditary angioedema (HAE) pharmacodynamics (PK) and pharmacodynamics (PD) will be presented at the 2021 American Society for Allergic Asthma and Immunology (AAAAI) Virtual Annual Meeting.
in two double-blind, placebo-controlled single dose studies, the PD effect was evaluated using the nonlinear mixed effect PK/PD model (using 12 mg and 22 mg doses, respectively) and compared with historical data.
PK/PD analysis shows that the average composite EC50 is 2.4 ng / mL and EC85 is 13.8 ng / mL.
25 percent of all subjects treated with PHA121 reported adverse events (AEs), the same rate as 25 percent of placebos.
all adverse events are mild or moderate and quickly disappear completely.
Peng Lu, chief medical officer of Pharvaris, said: "Oral PHA121 rapidly absorbs within 15 minutes with or without food and exceeds the expected effective treatment threshold.
alternative indicators of the use of refractive peptide excitation, pharmacological results suggest that a single oral dose of PHA121 may have a longer pharmacological effect than icatibant".